周三，TD Cowen重申了对Hims & Hers Health, Inc.（NYSE: HIMS）股票的买入评级，维持28.00美元的目标价。该公司的评论主要集中在最近FDA与外包设施协会（OFA）之间关于药物tirzepatide的法律进展。FDA提议的联合状态报告定于2024年11月21日发布，这可能会澄清该药物的供应状况。 TD Cowen的分析师强调了即将发布的报告的重要性及其对市场的 ...

旧金山——根据最近的SEC文件，Hims & Hers Health Inc. (NYSE:HIMS)的首席会计官Becklund Irene于2024年11月18日执行了一系列股票交易。 Irene行权获得472股A类普通股，每股价格为9.41美元。随后，她以每股19.42美元的价格出售了相同数量的股票，总销售价值为9,166美元。这些交易是根据2023年9月11日采用的预先安排的交易计划进行的 ...

Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The ...

Hims & Hers offers personalized telehealth services, with a stock price that reflects high-growth potential. See why we ...

Shares of Hims & Hers Health jumped after the company added former Food and Drug Administration official Deb Autor to its board. The stock was up 8.8% at $21.02 in Monday trading. Shares have doubled ...

Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Hims & Hers (NYSE: HIMS) is disrupting the healthcare market with its innovative patient treatment approach. Read More: Earn ...

Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS), the leading health and wellness platform, today announced Deb Autor, ...

Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.’s latest push into healthcare will ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...